Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Tuberculosis

  Free Subscription


27.03.2017

1 Am J Respir Crit Care Med
1 Antimicrob Agents Chemother
2 Clin Infect Dis
15 Eur Respir J
3 J Antimicrob Chemother
1 J Clin Microbiol
2 J Infect Dis
1 Lancet Respir Med
6 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Respir Crit Care Med

  1. DEDICOAT MJ, Gunther G, Crudu V, Duarte R, et al
    Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure.
    Am J Respir Crit Care Med. 2017 Mar 21. doi: 10.1164/rccm.201612-2585.
    PubMed     Text format    


    Antimicrob Agents Chemother

  2. XU J, Wang B, Hu M, Huo F, et al
    Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Mar 20. pii: AAC.00239.
    PubMed     Text format     Abstract available


    Clin Infect Dis

  3. PROANO A, Bravard MA, Lopez JW, Lee GO, et al
    Dynamics of Cough Frequency in Adults Undergoing Treatment for Pulmonary Tuberculosis.
    Clin Infect Dis. 2017 Jan 25. doi: 10.1093.
    PubMed     Text format     Abstract available

  4. MARKS SM, Mase SR, Bamrah Morris S
    Systematic Review, Meta-Analysis, and Cost Effectiveness of Treatment of Latent Tuberculosis Infection to Reduce Progression to Multidrug-Resistant Tuberculosis.
    Clin Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Text format     Abstract available


    Eur Respir J

  5. VAN DER PAARDT AL, Akkerman OW, Gualano G, Palmieri F, et al
    Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    

  6. VAN KAMPENHOUT E, Bolhuis MS, Alffenaar JC, Oswald LM, et al
    Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    

  7. UDWADIA ZF, Ganatra S, Mullerpattan JB
    Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India.
    Eur Respir J. 2017;49.
    PubMed     Text format    

  8. GARCIA-BASTEIRO AL, Miranda Ribeiro R, Brew J, Sacoor C, et al
    Tuberculosis on the rise in southern Mozambique (1997-2012).
    Eur Respir J. 2017;49.
    PubMed     Text format    

  9. LU P, Liu Q, Martinez L, Yang H, et al
    Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China.
    Eur Respir J. 2017;49.
    PubMed     Text format    

  10. ROTH DZ, Ronald LA, Ling D, Chiang LY, et al
    Impact of interferon-gamma release assay on the latent tuberculosis cascade of care: a population-based study.
    Eur Respir J. 2017;49.
    PubMed     Text format    

  11. BASTOS ML, Lan Z, Menzies D
    An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available

  12. BJORN-MORTENSEN K, Lillebaek T, Koch A, Soborg B, et al
    Extent of transmission captured by contact tracing in a tuberculosis high endemic setting.
    Eur Respir J. 2017;49.
    PubMed     Text format    

  13. KAMADA A, Amishima M
    QuantiFERON-TB(R) Gold Plus as a potential tuberculosis treatment monitoring tool.
    Eur Respir J. 2017;49.
    PubMed     Text format    

  14. PONTALI E, D'Ambrosio L, Centis R, Sotgiu G, et al
    Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.
    Eur Respir J. 2017;49.
    PubMed     Text format    

  15. YASSIN MA, Jaramillo E, Wandwalo E, Falzon D, et al
    Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated.
    Eur Respir J. 2017;49.
    PubMed     Text format    

  16. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available

  17. FALZON D, Schunemann HJ, Harausz E, Gonzalez-Angulo L, et al
    World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available

  18. SINKOU H, Hurevich H, Rusovich V, Zhylevich L, et al
    Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience.
    Eur Respir J. 2017;49.
    PubMed     Text format    

  19. VAN DER WERF MJ, Hollo V, Kodmon C, Dara M, et al
    Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.
    Eur Respir J. 2017;49.
    PubMed     Text format    


    J Antimicrob Chemother

  20. GURUMURTHY M, Verma R, Naftalin CM, Hee KH, et al
    Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial.
    J Antimicrob Chemother. 2017 Mar 18. doi: 10.1093.
    PubMed     Text format     Abstract available

  21. JAGANATH D, Schaaf HS, Donald PR
    Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.
    J Antimicrob Chemother. 2017 Mar 9. doi: 10.1093.
    PubMed     Text format     Abstract available

  22. CAVANAUGH JS, Jou R, Wu MH, Dalton T, et al
    Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
    J Antimicrob Chemother. 2017 Feb 20. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Clin Microbiol

  23. ANTHWAL D, Gupta RK, Bhalla M, Bhatnagar S, et al
    Direct detection of Rifampicin and Isoniazid resistance in sputum samples from tuberculosis patients by High Resolution Melt curve analysis.
    J Clin Microbiol. 2017 Mar 22. pii: JCM.02104-16. doi: 10.1128/JCM.02104.
    PubMed     Text format     Abstract available


    J Infect Dis

  24. HALLIDAY A, Whitworth H, Hermagild Kottoor S, Niazi U, et al
    Stratification of latent tuberculosis infection by cellular immune profiling.
    J Infect Dis. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format     Abstract available

  25. CLARK S, Lanni F, Marinova D, Rayner E, et al
    Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis.
    J Infect Dis. 2017 Jan 25. doi: 10.1093.
    PubMed     Text format     Abstract available


    Lancet Respir Med

  26. BURKI TK
    Tuberculosis missing from WHO bacteria list.
    Lancet Respir Med. 2017 Mar 14. pii: S2213-2600(17)30090.
    PubMed     Text format    


    PLoS One

  27. DROZNIN M, Johnson A, Johnson AM
    Multidrug resistant tuberculosis in prisons located in former Soviet countries: A systematic review.
    PLoS One. 2017;12:e0174373.
    PubMed     Text format     Abstract available

  28. KARAT AS, Tlali M, Fielding KL, Charalambous S, et al
    Measuring mortality due to HIV-associated tuberculosis among adults in South Africa: Comparing verbal autopsy, minimally-invasive autopsy, and research data.
    PLoS One. 2017;12:e0174097.
    PubMed     Text format     Abstract available

  29. ZHOU Y, van den Hof S, Wang S, Pang Y, et al
    Association between genotype and drug resistance profiles of Mycobacterium tuberculosis strains circulating in China in a national drug resistance survey.
    PLoS One. 2017;12:e0174197.
    PubMed     Text format     Abstract available

  30. FAN L, Shen H, Huang H, Yang R, et al
    Impairment of Wnt/beta-catenin signaling in blood cells of patients with severe cavitary pulmonary tuberculosis.
    PLoS One. 2017;12:e0172549.
    PubMed     Text format     Abstract available

  31. MOORES A, Riesco AB, Schwenk S, Arnvig KB, et al
    Expression, maturation and turnover of DrrS, an unusually stable, DosR regulated small RNA in Mycobacterium tuberculosis.
    PLoS One. 2017;12:e0174079.
    PubMed     Text format     Abstract available

  32. VIDYARTHI A, Khan N, Agnihotri T, Siddiqui KF, et al
    Antibody response against PhoP efficiently discriminates among healthy individuals, tuberculosis patients and their contacts.
    PLoS One. 2017;12:e0173769.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: